As we reported on July 30, Pfizer — the manufacturer of EpiPen — has announced a deal to merge its Upjohn generics business with Mylan, the marketer of EpiPen.
The EpiPen auto-injector, still the market leader for emergency epinephrine devices, has been the subject of worldwide shortages resulting from quality issues plaguing Prizer’s Meridian Medical Technologies unit. The unit has been cited by the FDA and is the subject of a federal investigation.
The transfer of Meridian to Mylan, which would place manufacture and marketing of EpiPen under a single company, was not considered part of the original deal. That may have changed.
“We’ve had some conversations with Mylan about that potentially transferring to Mylan as a supplement to the existing transaction, but nothing has been finalized to date yet,” Frank D’Amelio, Pfizer’s chief financial officer told Reuters.
Although consolidating all aspects of the EpiPen business could potentially streamline operations, it remains to be seen whether the new company would be able to fix EpiPen’s manufacturing woes.
The merger, if consummated, would close sometime in 2020.
Pfizer Issues Statement Extending the Expiration Date for Select Lots of EpiPen
